Neuland Laboratories Ltd. (IN:NEULANDLAB)
:NEULANDLAB
Top Page
Neuland Laboratories Ltd.
(NEULANDLAB)
Select Model
Select Model
Rating:60Neutral
Price Target:
₹14,753.00
▼(-3.36% Downside)
Action:ReiteratedDate:03/14/26
The score is driven primarily by solid financial performance (strong growth and balance sheet strength), partially offset by weak technical momentum (price below major DMAs with negative MACD) and an expensive valuation (very high P/E with a low dividend yield).
Positive Factors
Balance sheet strength
Neuland's robust balance sheet and high equity ratio provide durable financial flexibility to fund capacity expansion, regulatory compliance and long-term CMS contracts. Strong equity cushions downturns, supports supplier/customer confidence and lowers refinancing risk over time.
Negative Factors
EPS decline / volatility
A sharp EPS contraction of roughly -40% signals volatile net profitability. Persistent EPS weakness can erode retained earnings and limit reinvestment into capacity or R&D, reducing the firm's ability to sustain long-term earnings growth and withstand industry cycles.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Neuland's robust balance sheet and high equity ratio provide durable financial flexibility to fund capacity expansion, regulatory compliance and long-term CMS contracts. Strong equity cushions downturns, supports supplier/customer confidence and lowers refinancing risk over time.
Read all positive factors
Neuland Laboratories Ltd. (NEULANDLAB) vs. iShares MSCI India ETF (INDA)
Market Cap
₹180.27B
Dividend Yield0.08%
Average Volume (3M)2.41K
Price to Earnings (P/E)120.0
Beta (1Y)0.89
Revenue Growth0.34%
EPS Growth-14.13%
CountryIN
Employees1,643
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)37.00
Shares Outstanding12,829,889
10 Day Avg. Volume1,318
30 Day Avg. Volume2,408
Financial Highlights & Ratios
PEG Ratio-4.25
Price to Book (P/B)9.66
Price to Sales (P/S)10.27
P/FCF Ratio132.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)379.44
Revenue Forecast (FY)₹22.52B
Neuland Laboratories Ltd. Business Overview & Revenue Model
Company Description
Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics, cardiovascul...
How the Company Makes Money
Neuland Laboratories primarily makes money by manufacturing and selling active pharmaceutical ingredients (APIs) and by earning service and manufacturing revenue through contract development and manufacturing arrangements. A key revenue stream is ...
Neuland Laboratories Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
80
Positive
Cash Flow
72
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.91B | 14.34B | 15.16B | 11.61B | 9.23B | 9.18B |
| Gross Profit | 7.31B | 6.84B | 7.82B | 5.47B | 3.70B | 3.63B |
| EBITDA | 4.02B | 4.18B | 4.72B | 2.79B | 1.41B | 1.58B |
| Net Income | 2.40B | 2.60B | 3.00B | 1.64B | 638.22M | 806.31M |
Balance Sheet | ||||||
| Total Assets | 25.34B | 21.80B | 18.33B | 15.80B | 13.83B | 13.25B |
| Cash, Cash Equivalents and Short-Term Investments | 1.80B | 3.67B | 1.03B | 454.16M | 84.68M | 105.51M |
| Total Debt | 2.65B | 1.57B | 953.90M | 1.28B | 2.41B | 1.82B |
| Total Liabilities | 9.14B | 6.55B | 5.50B | 5.86B | 5.43B | 5.38B |
| Stockholders Equity | 16.20B | 15.25B | 12.83B | 9.94B | 8.41B | 7.86B |
Cash Flow | ||||||
| Free Cash Flow | -2.07B | 1.11B | 1.18B | 1.71B | -372.97M | 839.65M |
| Operating Cash Flow | -367.47M | 3.17B | 2.61B | 2.37B | 603.89M | 1.89B |
| Investing Cash Flow | -521.95M | -2.98B | -1.50B | -614.99M | -955.16M | -844.24M |
| Financing Cash Flow | -19.30M | 249.61M | -692.82M | -1.36B | 377.21M | -1.14B |
Neuland Laboratories Ltd. Technical Analysis
Positive
15265.60
Price Trends
12891.42
Positive
14368.68
Negative
14328.72
Negative
Market Momentum
41.78
Negative
66.23
Neutral
88.84
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NEULANDLAB, the sentiment is Positive. The current price of 15265.6 is above the 20-day moving average (MA) of 12449.36, above the 50-day MA of 12891.42, and above the 200-day MA of 14328.72, indicating a neutral trend. The MACD of 41.78 indicates Negative momentum. The RSI at 66.23 is Neutral, neither overbought nor oversold. The STOCH value of 88.84 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NEULANDLAB.
Neuland Laboratories Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹199.10B | 26.69 | ― | 0.57% | -3.79% | -20.88% | |
73 Outperform | ₹156.61B | 24.17 | ― | 0.24% | 8.14% | 5.18% | |
71 Outperform | ₹79.15B | 18.03 | ― | 0.44% | 14.80% | 1.35% | |
69 Neutral | ₹126.20B | 21.31 | ― | 0.31% | 11.41% | 19.22% | |
60 Neutral | ₹180.27B | 119.97 | ― | 0.08% | 0.34% | -14.13% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:NEULANDLAB
Neuland Laboratories Ltd.
14,050.60
3,116.31
28.50%
IN:CAPLIPOINT
Caplin Point Laboratories Limited
1,660.25
-51.77
-3.02%
IN:GRANULES
Granules India Limited
645.35
215.47
50.12%
IN:MARKSANS
Marksans Pharma Limited
174.65
-19.17
-9.89%
IN:NATCOPHARM
NATCO Pharma Limited
1,111.60
369.07
49.70%
Neuland Laboratories Ltd. Corporate Events
Neuland Laboratories Reports Loss of Share Certificate by Investor
Mar 12, 2026
Neuland Laboratories Ltd. has informed the stock exchanges that a shareholder, identified under folio number 0005239, has reported the loss of a physical share certificate representing 100 shares. The company has received a request from this share...
Neuland Labs Schedules Non-Deal Roadshows in Hong Kong and Singapore
Mar 3, 2026
Neuland Laboratories has announced a schedule of upcoming interactions with analysts and institutional investors as part of non-deal roadshows organized by BK Securities. These meetings will include both group and one-on-one sessions in Hong Kong ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.